Amgen takes option on Xencor's dual CD19/CD32d MAb for autoimmune disease
This article was originally published in Scrip
Executive Summary
Amgen and Xencor are to collaborate on the development of XmAb5871, an Fc-engineered monoclonal antibody targeting both CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.